{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:45:43Z","timestamp":1789933543121,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:00:00Z","timestamp":1362441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:00:00Z","timestamp":1362441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/leu.2013.69","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T07:44:29Z","timestamp":1362469469000},"page":"1310-1315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis"],"prefix":"10.1038","volume":"27","author":[{"given":"F J","family":"Giles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-E","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,5]]},"reference":[{"key":"BFleu201369_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd3252","volume":"10","author":"T Force","year":"2011","unstructured":"Force T, Kolaja KL . Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011; 10: 111\u2013126.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu201369_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","volume":"106","author":"H Cheng","year":"2010","unstructured":"Cheng H, Force T . Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010; 106: 21\u201334.","journal-title":"Circ Res"},{"key":"BFleu201369_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","volume":"59","author":"MH Kappers","year":"2012","unstructured":"Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59: 151\u2013157.","journal-title":"Hypertension"},{"key":"BFleu201369_CR4","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011\u20132019.","journal-title":"Lancet"},{"key":"BFleu201369_CR5","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204\u20135212.","journal-title":"J Clin Oncol"},{"key":"BFleu201369_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533\u2013539.","journal-title":"Am J Hematol"},{"key":"BFleu201369_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ajh.22051","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Letendre L . Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86: 610\u2013611.","journal-title":"Am J Hematol"},{"key":"BFleu201369_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347\u20131348.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201369_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841\u2013851.","journal-title":"Lancet Oncol"},{"key":"BFleu201369_CR10","doi-asserted-by":"crossref","unstructured":"Levato L, Cantaffa R, Kropp M, Magro D, Piro E, Molica S . Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia. 54th ASH Annual Meeting and Exposition 2012; (abstract 1679\u2014Poster Presentation).","DOI":"10.1182\/blood.V120.21.1679.1679"},{"key":"BFleu201369_CR11","doi-asserted-by":"crossref","unstructured":"Labussi\u00e8re-Wallet H, Guillermin Y, Etienne M, Barale A, Serrier C, Tigaud I et al. Analysis of clinical arterial and metabolic parameters in chronic phase CML patients on nilotinib in a single center cohort. 54th Annual ASH Annual Meeting and Exposition 2012; (abstract 3756).","DOI":"10.1182\/blood.V120.21.3756.3756"},{"key":"BFleu201369_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","volume":"286","author":"AT Hirsch","year":"2001","unstructured":"Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317\u20131324.","journal-title":"JAMA"},{"key":"BFleu201369_CR13","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu201369_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/028134398750003142","volume":"16","author":"JD Hooi","year":"1998","unstructured":"Hooi JD, Stoffers HEJH, Kester ADM, Rinkens PELM, Kaiser V, van Ree JW et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease: The Limburg PAOD Study. Scand J Prim Health Care 1998; 16: 177\u2013182.","journal-title":"Scand J Prim Health Care"},{"key":"BFleu201369_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/aje\/153.7.666","volume":"153","author":"JD Hooi","year":"2001","unstructured":"Hooi JD, Kester ADM, Stoffers HEJH, Overdijk MM, van Ree JW, Knottnerus JA . Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001; 153: 666\u2013672.","journal-title":"Am J Epidemiol"},{"key":"BFleu201369_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","volume":"110","author":"E Selvin","year":"2004","unstructured":"Selvin E, Erlinger TP . Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738\u2013743.","journal-title":"Circulation"},{"key":"BFleu201369_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2458-10-38","volume":"10","author":"MT Alzamora","year":"2010","unstructured":"Alzamora MT, Fores R, Baena-Diez JM, Pera G, Toran P, Sorribes M et al. The peripheral arterial disease study (PERART\/ARTPER): prevalence and risk factors in the general population. BMC Public Health 2010; 10: 38.","journal-title":"BMC Public Health"},{"key":"BFleu201369_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4065\/mcp.2010.0133","volume":"85","author":"JW Olin","year":"2010","unstructured":"Olin JW, Sealove BA . Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 2010; 85: 678\u2013692.","journal-title":"Mayo Clin Proc"},{"key":"BFleu201369_CR19","unstructured":"ICLUSIG (package insert)ARIAD Pharmaceuticals, Inc.: Cambridge, MA, USA 2012."},{"key":"BFleu201369_CR20","doi-asserted-by":"crossref","unstructured":"Schwarz M, Kim TD, Mirault T, Grille P, Rea D, Lindhorst R et al. Elevated risk of peripheral artery occlusive disease (PAOD) in nilotinib treated chronic phase chronic myeloid leukemia (CML) patients assessed by ankle-brachial-index (ABI) and duplex ultrasonography. 54th ASH Annual Meeting and Exposition 2012; (abstract 914).","DOI":"10.1182\/blood.V120.21.914.914"},{"key":"BFleu201369_CR21","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu201369_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400\u2009mg versus 800\u2009mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424\u2013430.","journal-title":"J Clin Oncol"},{"key":"BFleu201369_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu201369_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jacc.2005.10.009","volume":"47","author":"AT Hirsch","year":"2006","unstructured":"Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC\/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. A collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47: 1239\u20131312.","journal-title":"J Am Coll Cardiol"},{"key":"BFleu201369_CR25","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim D et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu201369_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1086\/527564","volume":"46","author":"D Periard","year":"2008","unstructured":"Periard D, Cavassini M, Taffe P, Chevalley M, Senn L, Chapuis-Taillard C et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46: 761\u2013767.","journal-title":"Clin Infect Dis"},{"key":"BFleu201369_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1160\/TH04-03-0148","volume":"92","author":"M Franchini","year":"2004","unstructured":"Franchini M . Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 2004; 92: 298\u2013304.","journal-title":"Thromb Haemost"},{"key":"BFleu201369_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1078155210378913","volume":"17","author":"NM Agostino","year":"2011","unstructured":"Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011; 17: 197\u2013202.","journal-title":"J Oncol Pharm Pract"},{"key":"BFleu201369_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","volume":"24","author":"M Lassila","year":"2004","unstructured":"Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 935\u2013942.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFleu201369_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1536\/ihj.51.272","volume":"51","author":"M Hatano","year":"2010","unstructured":"Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R . Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010; 51: 272\u2013276.","journal-title":"Int Heart J"},{"key":"BFleu201369_CR31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.5551\/jat.8730","volume":"18","author":"S Masuda","year":"2011","unstructured":"Masuda S, Nakano K, Funakoshi K, Zhao G, Meng W, Kimura S et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J Atheroscler Thromb 2011; 18: 1043\u20131053.","journal-title":"J Atheroscler Thromb"},{"key":"BFleu201369_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijcard.2011.02.024","volume":"159","author":"K Nakamura","year":"2011","unstructured":"Nakamura K, Akagi S, Ogawa A, Kusano KF, Matsubara H, Miura D et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2011; 159: 100\u2013106.","journal-title":"Int J Cardiol"},{"key":"BFleu201369_CR33","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/jcb.20993","volume":"99","author":"L Li","year":"2006","unstructured":"Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK . Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem 2006; 99: 1553\u20131563.","journal-title":"J Cell Biochem"},{"key":"BFleu201369_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804: 445\u2013453.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu201369_CR35","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1161\/CIRCRESAHA.109.213637","volume":"106","author":"C Franco","year":"2010","unstructured":"Franco C, Ahmad PJ, Hou G, Wong E, Bendeck MP . Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1. Circ Res 2010; 106: 1775\u20131783.","journal-title":"Circ Res"},{"key":"BFleu201369_CR36","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.2353\/ajpath.2009.080734","volume":"175","author":"PJ Ahmad","year":"2009","unstructured":"Ahmad PJ, Trcka D, Xue S, Franco C, Speer MY, Giachelli CM et al. Discoidin domain receptor-1 deficiency attenuates atherosclerotic calcification and smooth muscle cell-mediated mineralization. Am J Pathol 2009; 175: 2686\u20132696.","journal-title":"Am J Pathol"},{"key":"BFleu201369_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.109.207357","volume":"105","author":"C Franco","year":"2009","unstructured":"Franco C, Britto K, Wong E, Hou G, Zhu SN, Chen M et al. Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis. Circ Res 2009; 105: 1141\u20131148.","journal-title":"Circ Res"},{"key":"BFleu201369_CR38","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/CIRCRESAHA.107.170662","volume":"102","author":"C Franco","year":"2008","unstructured":"Franco C, Hou G, Ahmad PJ, Fu EY, Koh L, Vogel WF et al. Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res 2008; 102: 1202\u20131211.","journal-title":"Circ Res"},{"key":"BFleu201369_CR39","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224\u20132232.","journal-title":"J Clin Oncol"},{"key":"BFleu201369_CR40","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Kim D-, Issaragrilsil S, Clark RE, Reiffers J, Nicolini FE et al. ENESTnd 4-year update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome\u2013positive (Ph+) chronic myeloid leukemia in chronic phase. 54th ASH Annual Meeting and Exposition 2012; (abstract 1676).","DOI":"10.1182\/blood.V120.21.1676.1676"},{"issue":"6","key":"BFleu201369_CR41","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"T D Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; e-pub ahead of print 5 March 2013 doi:10.1038\/leu.2013.70.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201369","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:33:16Z","timestamp":1648744396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,5]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFleu201369"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.69","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,5]]},"assertion":[{"value":"18 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FJG, MJM, PDLC, AH, and GS have consulted for, and received research funding from, Novartis. FH, C-EO, CM, and RCW are Novartis employees and stockholders.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}